New immune cell combo takes on tough melanoma
NCT ID NCT05470283
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment for people with advanced melanoma that has stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells (TILs) that have been engineered to produce a protein called IL15, combined with a drug called acetazolamide. The study aims to find the safest dose and check for side effects in about 21 adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OBX-115 (engineered immune cells) and acetazolamide
What this could lead to
If it works, this could point toward a new treatment option for people with advanced melanoma that hasn't responded to standard immunotherapy.
What could go wrong
This is an early, small Phase 1 trial with only 21 participants, so it's mainly checking safety and dosing. The treatment may not shrink tumors or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States